Akebia Therapeutics, Inc.
AKBA
$3.19
$0.072.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 8.96% | 23.31% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.96% | 23.31% | |||
| Cost of Revenue | 31.26% | 0.47% | |||
| Gross Profit | 5.25% | 28.15% | |||
| SG&A Expenses | 3.16% | -6.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.59% | -22.86% | |||
| Operating Income | 3.74% | 235.43% | |||
| Income Before Tax | -95.96% | 126.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -95.96% | 126.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -95.96% | 126.80% | |||
| EBIT | 3.74% | 235.43% | |||
| EBITDA | 3.67% | 1,955.57% | |||
| EPS Basic | -96.54% | 124.93% | |||
| Normalized Basic EPS | -95.21% | 131.45% | |||
| EPS Diluted | -96.54% | 124.93% | |||
| Normalized Diluted EPS | -95.06% | 130.51% | |||
| Average Basic Shares Outstanding | 11.49% | 7.68% | |||
| Average Diluted Shares Outstanding | 12.21% | 10.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||